Enflame Shares Surge 200% in Shanghai AI Chip Debut 
UK Businesses Urge Government to Cut Electricity Levies 
Samsung Heavy Wins $1.22 Billion LNG Carrier and Tanker Deal 
MediaTek Unveils 2nm Dimensity 9600 Pro AI Chip 
US Treasury Yields Near 5% as Oil Fuels Inflation Fears 
Asian Stocks Steady as AI Shares Rebound Ahead of Fed Decision 
Bill Gates Warns Governments Are Unprepared for AI Disruption 
UK Economy Grows 0.4% in July, Beating Forecasts 
Z.AI Shares Slide 7% After $5 Billion Fundraising 
Saudi Oil Exports Face 4% Global Supply Threat as Pipeline Remains Shut 
China’s Global Times Slams Anthropic CEO’s AI Slowdown Plan as ‘Cold War’ Strategy 
Can Europe shake its Russia links for good? 
Hyundai Delays In-House ADAS, Turns to Nvidia 
BOJ Flags Import Costs and Yen Shocks as Persistent Inflation Risks 
Nvidia Eyes $10 Billion Investment in Anthropic IPO 
Hormuz Vessel Traffic Drops to Single Digits 
Add as a preferred source on Google
KT Corp. has collaborated with US-based NeuroSigma Inc. to build a business model and technology for electronic medicine to treat neurological disorders, such as attention deficit hyperactivity disorder (ADHD), depression, and epilepsy.
Under the partnership, KTS will support the development of the next version of NeuroSigma's external trigeminal nerve stimulation (eTNS®) system while producing and commercializing the device in South Korea.
NeuoSigma is credited for developing the first device cleared by the US Food and Drug Administration to treat pediatric ADHD--the Monarch external Trigeminal Nerve Stimulation system,
The telecom operator said NeuoSigma's pediatric ADHD electronic treatment has fewer side effects than other existing medication and is set to receive further clearance from the FDA on depression and epilepsy treatment using the technology.
